Search results
Is Eli Lilly Stock A Buy After Weight-Loss Drug Crushes Quarterly Sales Forecasts?
Investor's Business Daily· 5 days agoTrulicity, another diabetes treatment, had $1.46 billion in first-quarter sales, down 26% and below...
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
Zacks via Yahoo Finance· 5 days agoEli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises...
Eli Lilly's Weight-Loss Drug Still Going Strong, Boosts Annual Forecast
Benzinga via Yahoo Finance· 5 days agoThe volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio, and Jardiance,...
IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Investor's Business Daily· 4 days agoHe kept his in-line (neutral) rating on Eli Lilly stock. Sales of other key products, cancer drug...
Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 4 days agoThe financial overview indicates that LLY has experienced revenue growth driven by increased volume...
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Zacks via Yahoo Finance· 2 days agoLilly’s first-quarter results were soft as it beat estimates for earnings but missed the same for...
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
Zacks via Yahoo Finance· 4 days agoEli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity...
Eli Lilly’s stock jumps as first-quarter profit tops estimates amid strong sales of Mounjaro,...
Market Watch· 5 days agoEli Lilly & Co. shares gained 7% premarket on Tuesday after the company reported first-quarter...
Rybelsus vs. Ozempic: How These Drugs Compare
Healthline· 4 days agoRybelsus (semaglutide) and Ozempic (semaglutide) are prescription drugs used to treat type 2 diabetes. Rybelsus comes as an oral tablet, while Ozempic comes as an injectable liquid solution.
Eli Lilly (LLY) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 4 days agoRevenue in the rest of the world increased 31% in constant currency, primarily driven by volume growth from Mounjaro and to a lesser extent, Verzenio and...
